Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase IIa Clinical Study to Evaluate KAND567 against Cardiovascular Inflammation Associated with Myocardial Infarction in Patients Suffering from Myocardial Infarction

Trial Profile

A Phase IIa Clinical Study to Evaluate KAND567 against Cardiovascular Inflammation Associated with Myocardial Infarction in Patients Suffering from Myocardial Infarction

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 03 Sep 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs KAND-567 (Primary)
  • Indications Cardiovascular disorders; Inflammation; Myocardial infarction
  • Focus Therapeutic Use
  • Sponsors Kancera
  • Most Recent Events

    • 03 Sep 2019 According to an Kancera media release, the company plans to enter Phase II for myocardial infarction in the first half of 2020.
    • 06 Mar 2019 According to a Kancera media release, results from this study is expected in the second half of 2020.
    • 09 Feb 2019 According to a Kancera media release, the company plans to start this trial in the second half of 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top